Five different anti-prostate-specific membrane antigen (PSMA) antibodies confirm PSMA expression in tumor-associated neovasculature

Cancer Research

Volumn 59, Issue 13, 1999, Pages 3192-3198

  Chang, Sam S ^a   Reuter, Victor E ^a   Heston, W D W ^a   Bander, Neil H ^c   Grauer, Lana S ^b   Gaudin, Paul B ^a  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^b Hybritech Incorporated   (United States)

^c NEW YORK PRESBYTERIAN HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EPITOPE; MONOCLONAL ANTIBODY; PROSTATE SPECIFIC ANTIGEN;

ANTIGEN ANTIBODY REACTION; ANTIGEN EXPRESSION; ARTICLE; CANCER CELL; CANCER CELL CULTURE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MALIGNANT NEOPLASTIC DISEASE; PRIORITY JOURNAL; PROSTATE CANCER; PROTEIN LOCALIZATION; TISSUE SPECIFICITY; TUMOR VASCULARIZATION;

ANTIBODIES, MONOCLONAL; ANTIGENS, NEOPLASM; ANTIGENS, SURFACE; BREAST NEOPLASMS; CARBOXYPEPTIDASES; CARCINOMA, RENAL CELL; FEMALE; GLUTAMATE CARBOXYPEPTIDASE II; HUMANS; MALE; NEOPLASMS; NEOVASCULARIZATION, PATHOLOGIC; PROSTATE; PROSTATIC NEOPLASMS; TESTICULAR NEOPLASMS; TRANSFECTION; TUMOR CELLS, CULTURED; URINARY BLADDER NEOPLASMS;

EID: 0033168844     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (43)

1. Horoszewicz, J. S., Kawinski, E., and Murphy, G. P. Monoclonal antibodies to a new antigenic marker in epithelial cells and serum of prostatic cancer patients. Anticancer Res., 7: 927-936, 1987.
2. Israeli, R. S., Powell, C. T., Fair, W. R., and Heston, W. D. W. Molecular cloning of a complementary DNA encoding a prostate-specific membrane antigen. Cancer Res., 53: 227-230, 1993.
3. Rinker-Schaefer, C. W., Hawkins, A. L., Su, S., Israeli, R. S., Griffin, C. A., Isaacs, J. T., and Heston, W. D. W. Localization and physical mapping of the prostate-specific membrane antigen (PSM) gene to human chromosome 11. Genomics, 30: 105-108, 1995.
4. Leek, J., Lench, N., Maraj, B., Bailey, A.. Carr, I. M., Andersen, S., Cross, J., Whelan, P., MacLennan, D. M., and Markham, A. F. Prostate-specific membrane antigen: evidence for the existence of a second related human gene. Br. J. Cancer, 72: 583-588, 1995.
5. O'Keefe, D. S., Su, S. L., Bacich, D. J., Horiguchi, Y., Luo, Y., Powell, C. T., Zandvliet, D., Russell, P. J., Molloy, P. L, Nowak, N. J., Shows, T. B., Mullins, C., Vonder Haar, R. A., Fair, W. R., and Heston, W. D. W. Mapping, genomic organization, and promoter analysis of the human prostate-specific membrane antigen gene. Biochim. Biophys. Acta, 1443: 113-127, 1998.
6. Lopes, A. D., Davis, W. L., Rosenstraus, M. J . Uveges, A. J., and Gilman, S. C. Inununohistochemical and pharmacokinetic characterization of the site-specific immunoconjugate CYT-356 derived from antiprostate monoclonal antibody 7E11-C5. Cancer Res., 50, 6423-6429, 1990.
7. Sokoloff, R. L., Norton, K. C., Gasior, C. L., Marker, K. M., and Grauer, L. S. Quantification of prostate specific membrane antigen (PSMA) in human tissues and subcellular fractions. Proc. Am. Assoc. Cancer Res., 39: 265, 1998.
8. Wright. G. L., Haley, C., Beckett, M. L., and Schellhammer, P. F. Expression of prostate-specific membrane antigen in normal, benign, and malignant prostate tissues. Urol. Oncol., 1: 18-28, 1995.
9. Bostwick, D. G., Pacelli, A., Blute, M., Roche P., and Murphy, G. P. Prostate-specific membrane antigen expression in prostatic intraepithelial neoplasia and adenocarcinoma: a study of 184 cases. Cancer (Phila.). 82: 2256-2261, 1998.
10. Kawakami, M., and Nakayama, J. Enhanced expression of prostate-specific membrane antigen gene in prostate cancer as revealed by in situ hybridization. Cancer Res., 57: 2321-2324, 1997.
11. Wright, G. L., Grob, B. M., Haley, C., Grossman, K., Newall, K., Petrylak, D., Troyer, J., Konchuba, A., Schellhammer, P. F., and Moriarty, R. Upregulation of prostate-specific membrane antigen after androgen-deprivation therapy. Urology, 48: 326-334, 1996.
12. Su, S. L., Huang, I-P., Fair, W. R., Powell, C. T., and Heston, W. D. W. Alternatively spliced variants of prostate-specific membrane antigen RNA: ratio of expression as a potential measurement of progression. Cancer Res., 55: 1441-1443, 1995.
13. Grauer, L. S., Lawler, K. D., Marignac, J. L., Kumar, A., Goel, A. S., and Wolfert, R. L. Identification, purification, and subcellular localization of prostate-specific membrane antigen PSM' protein in the LNCaP prostatic carcinoma cell line. Cancer Res., 58: 4787-4789, 1998.
14. Troyer, J. K., Feng, Q., Beckett, M. L., and Wright, G. L., Jr. Biochemical characterization and mapping of the 7E11-C5.3 epitope of the prostate-specific membrane antigen. Urol. Oncol., 1: 29-37, 1995.
15. Silver, D. A., Pellicer, I., Fair W. R., Heston W. D. W., and Cordon-Cardo, C. Prostate-specific membrane antigen expression in normal and malignant human tissues. Clin. Cancer Res., 3: 81-85, 1997.
16. Liu, H., Moy P., Xia Y., Kim, S., Rajasekaran, A. K., Navarro, V., Knudsen, B., and Bander, N. H. Monoclonal antibodies to the extracellular domain of prostate-specific membrane antigen also react with tumor vascular endothelium. Cancer Res., 57: 3629-3634, 1997.
17. Pinto, J. T., Suffoletto, B. P., Berzin, T. M., Qiao, C. H., Lin, S., Tong, W. P., May, F., Mukherjee, B., and Heston, W. D. W. Prostate specific membrane antigen: a novel folate hydrolase in human prostatic carcinoma cells. Clin. Cancer Res., 2: 1445-1451, 1996.
18. Carter, R. E., Feldman, A. R., and Coyle, J. T. Prostate-specific membrane antigen is a hydrolase with substrate and pharmacologic characteristics of a neuropeptidase. Proc. Natl. Acad. Sci. USA, 93: 749-753, 1996.
19. Carter, R. L., Barczak, A. K., Speno, H., and Coyle, J. T. Molecular characterization of human brain n-acetylated α-linked acidic dipeptidase (NAALADase). J. Pharmacol. Exp. Ther., 285: 1020-1025, 1998.
20. Barrett, A. J. Nomenclature Committee of the International Union of Biochemistry and Molecular Biology (NC-IUBMB). Enzyme Nomenclature. Recommendations 1992. Supplement 4: Corrections and Additions (1997). Eur. J. Biochem., 250: 1-6, 1997.
21. Troyer, J. K., Beckett, M. L., and Wright, G. L., Jr. Location of prostate-specific membrane antigen in the LNCaP prostate carcinoma cell line. Prostate, 30: 232-242, 1997.
22. 111indium-labeled monoclonal antibody CYT-356. J. Urol., 152: 1952-1955, 1994.
23. 111indium-labeled CYT-356 for the detection of occult prostate cancer recurrence. J. Urol., 152: 1490-1495, 1994.
24. Murphy, G. P. Radioscintiscanning of prostate cancer. Cancer (Phila.), 75: 1819-1833, 1995.
25. 111Indium-capromab pendetide in the evaluation of patients with residual or recurrent prostate cancer after radical prostatectomy. J. Urol., 159: 2041-2047, 1998.
26. Shibusa, T., Shijubo, N., and Abe, S. Tumor angiogenesis and vascular endothelial growth factor expression in stage I lung adenocarcinoma. Clin. Cancer Res., 4: 1483-1487, 1998.
27. Siitonen, S. M., Haapasalo, H. K., Rantala, I. S., Helin, H. J., and Isola, J. J. Comparison of different immunohistochemical methods in the assessment of angiogenesis: lack of prognostic value in a group of 77 selected node-negative breast carcinomas. Mod. Pathol., 8: 745-752, 1995.
28. Emoto, M., Iwasaki, H., Mimura, K., Kawarabayashi, T., and Kikuchi, M. Differences in the angiogenesis of benign and malignant ovarian tumors demonstrated by analyses of color Doppler ultrasound, immunohistochemistry, and microvessel density. Cancer (Phila.), 80; 899-907, 1997.
29. Maher, T. M., and Lee, A. H. Vascular density does not predict future metastatic disease in clinical stage 1 non-seminomatous germ cell tumours of the testis. Histopathology, 32: 217-224, 1998.
30. Bettencourt, M. C., Bauer, J. J., Sesterhenn, J. A., Connelly, R. R., and Moul, J. W. CD34 immunohistochemical assessment of angiogenesis as a prognostic marker for prostate cancer recurrence after radical prostatectomy. J. Urol., 160: 459-465, 1998.
31. Barren, R. J., III, Holmes, E. H., Boynton, A. L., Misrock, S. L., and Murphy, G. P. Monoclonal antibody 7E11. C5 staining of viable LNCaP cells. Prostate, 30: 65-68, 1997.
32. Muldoon, R. T., Ross, D. M., and McMartin, K. E. Folate transport pathways regulate urinary excretion of 5-methyltetrahydrofolate in isolate perfused rat kidney. J. Nutr., 126: 242-250, 1996.
33. Halsted, C. H., Ling, E. H., Luthi-Carter, R., Villaneuva, J. A., Gardner, J. M., and Coyle, J. T. Folypoly-gamma-glutamate carboxypeptidase from pig jejunum. Molecular characterization and relation to glutamate carboxypeptidase II. J. Biol. Chem., 273: 20417-20424, 1998.
34. Berger, U. V., Carter, R. E., and Coyle, J. T. Immunocytochemical localization of N-acetylaspartyl glutamate, its hydrolyzing enzyme NAALADase, and the NMDAR-1 receptor at a vertebrate neuromuscular junction. Neuroscience, 64: 847-850, 1995.
35. Murphy, G., Tjoa, B., Ragde, H., Kenny, G., and Boynton, A. Phase I clinical trial: T-cell therapy for prostate cancer using autologous dendritic cells pulsed with HLA-A0201 specific peptides from prostate specific membrane antigen. Prostate, 29: 371-380, 1996.
36. Zhang, S., Zhang, H. S., Reuter, V. E., Slovin, S. F., Scher, H. I., and Livingston, P. O. Expression of potential target antigens for immununotherapy on primary and metastatic prostate cancers. Clin. Cancer Res., 4: 295-302, 1998.
37. Murphy, G. P., Greene, T. G., Tino, W. T., Boynton, A. L., and Holmes, E. H. Isolation and characterization of monoclonal antibodies specific for the extracellular domain of prostate specific membrane antigen. J. Urol., 160: 2396-2401, 1998.
38. Folkman, J. Anti-angiogenesis: new concept for therapy of solid tumor. Ann. Surg., 175: 409-416, 1972.
39. Folkman, J. How is blood vessel growth regulated in normal and neoplastic tissue? Cancer Res., 46: 467-473, 1986.
40. Ellis, L. M., and Fidler, I. J. Angiogenesis and metastasis. Eur. J. Cancer, 32A: 2451-2460, 1996.
41. 111Indium-capromab pendetide unexpectedly localizes to renal cell carcinoma. J. Urol., 161: 597-598, 1999.
42. Gottlinger, H. G., Funke, I., Johnson, J. P., Gokel, J. M., and Riethmuller, G. The epithelial cell surface antigen 17-1A, a target for antibody-mediated tumor therapy: its biochemical nature, tissue distribution, and recognition by different monoclonal antibodies. Int. J. Cancer, 38: 47-53, 1986.
43. Pegram, M. D., Lipton, A., Hayes, D. F., Weber, B. L., Baselga, J. M., Tripathy, D., Baly D., Baughman, S. A., Twadell, T., Glaspy, J. A., and Slamon, D. J. Phase II study of receptor-enhanced chemosensitivity using recombinant humanized anti-p185HER2/neu monoclonal antibody plus cisplatin in patients with HER2/neu-overexpressing metastatic breast cancer refractory to chemotherapy treatment. J. Clin. Oncol., 16: 2659-2671, 1998.